IFNA1 and type 1 diabetes mellitus: Meyer et al. also proposed that type I IFN autoantibodies may have disease ameliorating activity and protect patients with APS1 from developing type 1 diabetes, based on the absence of IFN neutralizing autoantibodies in a small number of APS1 subjects with type 1 diabetes (n = 8).